METAFORA BIOSYSTEMS

Their core work

Metafora Biosystems is a Paris-based biotech SME developing diagnostic tools based on cellular metabolism. Their METAdiag platform detects serious diseases linked to abnormal cellular energetics — how cells consume and produce energy — which provides a diagnostic angle distinct from classic genetic or protein biomarkers. The company turns metabolic biology into clinical-grade tests aimed at earlier and more accurate disease detection, with a clear focus on bringing a single product line from feasibility through to market.

What they specialise in

How they've shifted over time

With only two H2020 projects — both on the same METAdiag product — the evolution is a classic SME Instrument trajectory rather than a thematic shift. In 2017 they secured a Phase 1 feasibility grant (EUR 50K); in 2018 they won Phase 2 development funding (EUR 3.2M) to build out the same metabolic diagnostic platform. The story is depth, not breadth: one focused product line scaled from concept validation toward clinical deployment.

They are moving from R&D into commercial deployment of a single, focused metabolic diagnostic product — a good partner for clinical validation, distribution, or indication-expansion discussions rather than early-stage exploratory research.

How they like to work

Both H2020 grants are single-beneficiary SME Instrument projects with no consortium partners listed, so their EU footprint reflects self-directed company development rather than collaborative consortium work. They coordinate by default because they are the sole beneficiary. A partner should expect a focused product company that has proven it can manage a EUR 3M EU grant alone, but not yet an experienced consortium-builder.

No consortium partners recorded in H2020 — both projects were single-beneficiary SME Instrument grants. Any external network (clinical collaborators, suppliers, investors) would sit outside the H2020 dataset.

What sets them apart

Metafora focuses on an unusual diagnostic angle — cellular metabolism and bioenergetics — rather than the more crowded genomics or protein-biomarker spaces. They have already cleared the SME Instrument Phase 1-to-Phase 2 gate, meaning EU evaluators twice validated the commercial potential of their technology. For a partner, that signals a company with a defined product, EU-vetted business case, and EUR 3M+ of development runway behind them.

Highlights from their portfolio

• METAdiag (SME-2)
  EUR 3.2M Phase 2 grant in 2018 — the company's flagship project, funding full development of a metabolic diagnostic platform for serious diseases.
• METAdiag (SME-1)
  The 2017 EUR 50K feasibility grant that preceded and unlocked the Phase 2 award, showing a successful progression through the SME Instrument pipeline.